Daewoong Introduced Innovative Diabetes Drug Enavogliflozin to Address Indonesia’s Growing Cases
(Jakarta, November 28, 2024) Daewoong announced the latest updates on its SGLT-2 inhibitor research to endocrinologists, internists, and general practitioners at the Jakarta Diabetes Meeting (JDM) on November 23-24, 2024. JDM is a prestigious annual scientific conference focused on diabetes mellitus. Now in its 33rd year, the event attracted over 400 healthcare professionals from across the country.
Daewoong introduced its novel drug, Enavogliflozin, first Korean SGLT-2 inhibitor developed in-house. Enavogliflozin, reduce blood sugar by inhibiting the kidneys from reabsorbing glucose, resulting in its elimination through urine. This mechanism not only eases the burden on the kidneys and heart but also lowers the risk of kidney and heart failure by simultaneously excreting sodium and glucose.
“We are extremely pleased to introduce our self-developed diabetes treatment at the Jakarta Diabetes Meeting,” said Dr. Deski from Daewoong Pharmaceutical’s Global Clinical Team. “We are thrilled by the significant attention from doctors, given the dramatic rise in prevalence for T2DM in Indonesia.”
According to the International Diabetes Federation (IDF), Indonesia ranks fifth worldwide for the highest number of diabetes patients, with 19.5 million adults and a prevalence rate of 10.8% in 2021, projected to rise to 28.6 million by 2045.
Enavogliflozin, with a dosage as low as 0.3 mg—less than 1/30th of existing SGLT-2 inhibitors—has demonstrated equivalent or superior efficacy. It outperforms dapagliflozin, the first-ever global SGLT-2 inhibitor.
Key diabetes management indicators—including fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), urinary glucose excretion rate (UGCR), and the insulin resistance index (HOMA-IR)—showed significant improvement in patients with impaired kidney function who used Enavogliflozin. After 24 weeks of treatment, 78.1% of patients on Enavogliflozin achieved an HbA1c level below 7%, compared to 65.7% for dapagliflozin. Enavogliflozin also reduced fasting blood glucose more effectively and increased urinary glucose excretion by 31%, with approximately 60% greater improvement in insulin resistance.
Based on Enavogliflozin’s outstanding results, Daewoong expects to offer an excellent treatment option for type 2 diabetes patients in Indonesia.
Seongsoo Park, CEO of Daewoong Pharmaceutical, stated, “We continue to collaborate with renowned experts worldwide, including those in Indonesia, to advance the adoption of Enavogliflozin as the latest treatment for diabetes. Daewoong is dedicated to delivering premium-quality medications that enhance the quality of life globally, including in Indonesia.”
For two decades, Daewoong has viewed Indonesia not just as an international market but as a key collaborative partner for growth since opening its Jakarta branch in 2005. In 2009, Daewoong began providing scholarships and internship programs for university students. In 2012, Daewoong established Indonesia's first biopharmaceutical facility, Daewoong Infion, which facilitates technology transfer for biopharmaceutical production and offers treatments like EPO, a treatment for anemia, and EGF, a treatment for diabetic foot ulcers.
Furthermore, since 2018, Daewoong has expanded its research infrastructure by opening three laboratories: the Bio Technology Research Center in 2018, the Bio Analytic Center in 2022 at the University of Indonesia (UI), and the Daewoong Drug Delivery System Laboratory (DDS) at Institut Teknologi Bandung (ITB), which was launched in 2024. Additionally, Daewoong has collaborated with a renowned gastroenterologist since August to pioneer a clinical trial for GERD treatment using Fexuprazan.
- ## -
